{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-324457","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.547857+00:00","generated_at":"2026-06-28T10:47:08.902754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M","bullets":["Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).","Net income $12.6M ($0.09 diluted EPS) vs $20.8M ($0.19) in Q3 2020; adj. EBITDA $21.7M (19% margin).","FY2021 guidance: net revenue $458-470M (35-39% growth); Advanced Wound Care $425-434M, PuraPly $196-204M.","Cash $102.7M, debt $83.2M as of Sept 30, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-324457","json":"https://secwatch.observer/filing/0001193125-21-324457.json","markdown":"https://secwatch.observer/filing/0001193125-21-324457.md","text":"https://secwatch.observer/filing/0001193125-21-324457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000119312521324457/0001193125-21-324457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000119312521324457/d234616d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:47:08.902754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}